biosimilar programs pbms - SERP Analysis

https://www.pcmanet.org/pbms-innovating-to-increase-biosimilar-use-lower-rx-costs/

https://www.pcmanet.org/pbms-are-breaking-down-barriers-to-expand-access-to-biosimilars-and-lower-consumer-costs/

https://www.ajmc.com/view/the-biosimilar-shift-how-pbms-are-reshaping-formularies

https://www.drugchannels.net/2025/04/the-big-three-pbms-2025-formulary.html

https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-payer-and-pbm-policies

https://www.forbes.com/sites/joshuacohen/2025/03/05/patient-access-to-cheaper-biosimilar-drugs-varies-significantly-across-pharmacy-benefit-managers/

https://www.drugchannels.net/2024/04/the-big-three-pbms-2024-formulary.html

https://www.beckershospitalreview.com/pharmacy/pbms-push-private-label-biosimilars-in-2025-formularies/

https://www.ajmc.com/view/biosimilar-adoption-legislative-action-with-pbms-jc-scott

https://www.statnews.com/2024/08/01/pbm-biosimilar-drugs-ftc-action-needed-anti-competitive-practices/

https://www.managedhealthcareexecutive.com/view/pbms-start-to-embrace-biosimilars

https://accessiblemeds.org/resources/blog/redesigned-medicare-drug-program-allows-pbms-deny-lower-cost-generics-biosimilars/

https://www.managedhealthcareexecutive.com/view/the-power-of-pbms-and-biosimilars-2025-launches-of-the-stelara-biosimilars-the-ira-and-interchangeability-q-a-with-craig-burton-mba

https://www.centerforbiosimilars.com/view/understanding-biosimilars-through-education-and-pbm-formulary-perspective

https://waysandmeans.house.gov/2025/04/10/four-key-moments-hearing-on-the-health-of-the-biosimilar-market/

https://www.sequoia.com/2024/12/how-biosimilars-can-significantly-reduce-pharmacy-costs-for-employers/

https://www.beckershospitalreview.com/pharmacy/big-3-pbm-formularies-favor-private-label-biosimilars.html

https://innovativerxstrategies.com/biosimilar-strategy-recommendations/

https://mmaeast.com/blog/biosimilars-impact-to-pbms-formulary-rebate-language/

https://phrma.org/blog/its-pbms-not-patents-blocking-competition

https://www.epiphanyrx.com/the-fast-five-still-buzzing-about-biosimilars/

https://www.zs.com/insights/pbms-and-biosimilar-drug-savings-opportunities

https://truveris.com/prepare-for-biosimilar-drugs/

https://biosimilarscouncil.org/news/new-data-shows-pbms-blocking-patient-access-to-biosimilar-insulin-despite-growing-demand/

https://navitus.com/resources/real-world-data-demonstrates-successful-transitions-from-humira-to-biosimilars/

https://www.hcplive.com/view/the-role-of-pharmacy-benefit-managers-and-payers-in-accessing-adalimumab-biosimilars

https://drugstorenews.com/aam-avalere-study-shows-pbms-continue-block-patient-access-biosimilars

https://www.nationalalliancehealth.org/wp-content/uploads/NationalAlliance_Biosimilars-Playbook_FINAL.pdf

https://www.bbrown.com/us/insight/will-biosimilars-help-save-employers-money/

https://www.forbes.com/sites/joshuacohen/2024/11/10/rebate-game-played-by-pbms-and-drug-makers-limits-biosimilar-competition/

https://aishealth.mmitnetwork.com/blogs/radar-on-drug-benefits/pbms-1q-earnings-calls-are-all-about-biosimilar-glp-1-programs

https://biosimilarscouncil.org/resource/pharmacy-benefit-managers-are-blocking-patient-access-to-biosimilar-insulin/

https://www.psgconsults.com/blog/pbm-moves-spur-humira-biosimilar-uptake-but-raise-questions/

https://www.zs.com/insights/pharmacy-benefit-is-a-whole-new-ball-game-for-biosimilars

https://archimedesrx.com/archimedes-announces-biosimilars-first-an-industry-leading-program-to-drive-biosimilar-adoption-in-2024/

https://www.cvshealth.com/news/pbm/cvs-caremark-accelerates-biosimilars-adoption-through-formulary-changes.html

https://biosimilarsforum.org/wp-content/uploads/Biosimilars-Forum-Response-to-FTC-Request-for-Comment-on-PBMs-May-24-2022.pdf

https://www.washingtonpost.com/politics/2023/12/19/market-biosimilars-is-funky-industry-thinks-pbms-are-blame/

https://www.businesswire.com/news/home/20250228980860/en/SmithRx-Introduces-Stelara-Biosimilars-to-Its-Autoimmune-Program-Helping-Clients-Save-a-Projected-%2414.5M-in-Prescription-Drug-Costs

https://www.pharmacytimes.com/view/ncpa-biosimilar-forum-voice-support-for-pbm-reform-bill

https://www.modernhealthcare.com/insurance/express-scripts-humira-biosimilars-cvs-caremark

https://www.axios.com/2022/02/17/humira-biosimilars-pbm-health-plan-drug-prices

https://kffhealthnews.org/news/article/humira-abbvie-biosimilar-biologic-savings-pbm-rebates/

https://www.smithrx.com/blog/what-does-a-pbm-do-to-reduce-costs

https://www.primetherapeutics.com/w/prime-therapeutics-joins-other-pbms-in-adding-humira-biosimilars

https://gastro.org/news/whats-new-in-the-fight-for-pbm-reform-and-access-to-biosimilars/

https://www.evernorth.com/articles/biosimilars-help-lower-costs-and-foster-innovation-pharmacy-benefits

https://innovativerxstrategies.com/biosimilars/

https://www.modernhealthcare.com/insurance/cvs-caremark-express-scripts-optumrx-biosimilars

https://aishealth.mmitnetwork.com/blogs/health-plan-weekly/pbms-boost-biosimilars-back-new-interchangeability-policy

https://pmc.ncbi.nlm.nih.gov/articles/PMC10398129/

https://biosimilarsrr.com/2025/04/09/biosimilar-hearings-day-in-congress/

https://www.fiercehealthcare.com/payers/pbm-serve-you-rx-add-2-stelara-biosimilars-its-specialty-formulary

https://oversight.house.gov/release/hearing-wrap-up-pharmacy-benefit-managers-push-anticompetitive-drug-pricing-tactics-to-line-their-own-pockets%EF%BF%BC/

https://www.biosimilardevelopment.com/doc/archimedes-announces-biosimilars-first-drive-biosimilar-adoption-0001

https://www.ispor.org/conferences-education/conferences/past-conferences/ispor-2024/program/program/session/intl2024-3895/138148

https://alliant.com/news-resources/capturing-savings-from-biosimilars-what-to-do-now/

https://www.evernorth.com/esfacts/key-topics/driving-drug-competition-to-lower-cost

https://www.linkedin.com/posts/biosimscouncil_pbm-schemes-to-control-biosimilar-humira-activity-7221207232485486593-JlAV

https://www.cap-rx.com/insights/will-biosimilar-rebates-pass-through

https://transparentrx.com/biosimilar-drugs-are-gaining-market-share

https://firstwordpharma.com/story/5948751

https://www.eric.org/wp-content/uploads/2020/03/JHU-Savings-Opportunities-for-Large-Employers.pdf

https://www.researchgate.net/publication/272083388_Biosimilar_Competition_In_The_United_States_Statutory_Incentives_Payers_And_Pharmacy_Benefit_Managers

https://www.segalco.com/consulting-insights/archive/reports-and-surveys/2020/04/biosimilar-drugs

https://www.ashp.org/About-ASHP/ceo-blogs/recent-blogs/pbm-practices-it-is-time-for-policymakers-to-act

https://www.hirc.com/PBM-specialty

https://www.smithrx.com/blog/introducing-stelara-biosimilars-to-connect-360-projecting-14-5m-in-client-savings

https://www.mercer.com/en-us/insights/us-health-news/understanding-the-debate-over-pbms/

https://news.calpers.ca.gov/calpers-health-team-pushes-for-broader-acceptance-of-biosimilars/

https://www.the-rheumatologist.org/tag/pharmacy-benefit-managers-pbms/

https://biosimilarsforum.org/resources/

https://selecthealth.org/scripius/industry-insight/adopting-biosimilars

https://www.drugtopics.com/view/lowering-patient-drug-costs-with-biosimilars-can-happen-when-the-right-teams-come-together

https://www.jmcp.org/doi/10.18553/jmcp.2020.20213

https://primetherapeutics.com/w/biosimilar-basics-part-3-getting-biosimilars-to-market

https://higherlogicdownload.s3.amazonaws.com/MBGH/ef998dc2-0de9-4904-b6d7-a36b4c0cef4b/UploadedImages/Action_Briefs/2025/Biosimilars/Biosimilars_Action_Brief_Final.pdf

https://safebiologics.org/asbm-adds-module-on-pbm-practices-to-ohio-state-university-biosimilars-course/

https://www.ipsos.com/en-us/us-biosimilars-greater-access-and-new-commercial-models

https://papers.ssrn.com/sol3/Delivery.cfm/5126123.pdf?abstractid=5126123&mirid=1

https://www.risk-strategies.com/hubfs/Consulting/White%20Paper%20Developments%20Considerations%20Biosimilar%20Landscape.pdf?hsLang=en

https://navitus.com/

https://serveyourx.com/news-blog/announcing-biosimilar-advantage-formulary/

https://www.dhhs.nh.gov/sites/g/files/ehbemt476/files/documents2/pdabpolicybrief-pharmacistsbiosimilarsubstitutionrecommendation-draft042125.pdf

https://accessiblemeds.org/wp-content/uploads/2025/01/AAM-2024-Generic-Biosimilar-Medicines-Savings-Report.pdf

https://viviohealth.com/wp-content/uploads/2024/07/Vivio-Biosimilars-Case-Study-Aug-2020.pdf

https://www.rand.org/pubs/periodicals/health-quarterly/issues/v7/n4/03.html

https://www.oneoncology.com/blog/no-good-deed-goes-unpunished-how-pbm-mandates-increase-practice-variability

https://phrma.org/blog/pbms-using-340b-program-to-drive-profits-at-patients-expense

https://www.americanprogress.org/article/5-things-to-know-about-pharmacy-benefit-managers/

https://www.priorauthtraining.org/what-are-biosimilars/

https://www.ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdf

https://www.corpsyn.com/knowledge-center/emerging-rx-trends/

https://www.geneonline.com/big-three-pbms-2025-formularies-prioritize-private-label-biosimilars-over-humira/

https://provcomm.ibx.com/pnc-ibc/news/Pages/Affordable-treatments-start-with-biosimilars.aspx

https://www.schauergroup.com/resource-library/trends-to-watch-glp-1-drugs-biosimilars-pbm-lawsuit/

https://apexbg.com/pharmacy-benefits-challenges-with-biosimilars/

https://friendsofcancerresearch.org/wp-content/uploads/The-Future-of-U.S.-Biosimilars_0.pdf

https://center-forward.org/basic/understanding-biosimilars-a-balanced-analysis/